Tag Archive for: GSBR-1290

After nixing a twice-daily version of its oral GLP-1 agonist, Pfizer is hoping to break into the weight-loss space with a once-daily version, but experts question its outlook.

The drug, GSBR-1290, belongs to the same class of treatments as Novo Nordisk’s blockbuster weight-loss drug Wegovy and Eli Lilly’s (LLY.N) diabetes drug Mounjaro.